Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/131252
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSicras Mainar, Antoni-
dc.contributor.authorSánchez-Álvarez, Luis-
dc.contributor.authorNavarro-Artieda, Ruth-
dc.contributor.authorDarbà, Josep-
dc.date.accessioned2019-04-03T11:42:45Z-
dc.date.available2019-04-03T11:42:45Z-
dc.date.issued2018-12-
dc.identifier.issn1476-511X-
dc.identifier.urihttp://hdl.handle.net/2445/131252-
dc.description.abstractHigh blood lipoprotein concentrations are one of the major risk factors for cardiovascular diseases. Drug therapy is the base of treatment; statins in particular. Both brand-name and generic presentations are available for statin therapy of high cholesterol levels. Factors that may influence their use in routine medical practice include, among others, patient persistence and adherence to treatment as prescribed by physicians. The aim of this retrospective analysis was to provide real-world evidence of treatment persistence and adherence and their consequences on economic and patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain.-
dc.format.extent16 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherBioMed Central-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1186/s12944-018-0918-y-
dc.relation.ispartofLipids In Health And Disease, 2018, vol. 17, num. 277, p. 01-16-
dc.relation.urihttps://doi.org/10.1186/s12944-018-0918-y-
dc.rightscc-by (c) Sicras Mainar, Antoni et al., 2018-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Economia)-
dc.subject.classificationSistemes d'administració de medicaments-
dc.subject.classificationColesterol-
dc.subject.classificationPrescripció de medicaments-
dc.subject.classificationAnàlisi econòmica-
dc.subject.classificationPolítica sanitària-
dc.subject.classificationAnàlisi cost-benefici-
dc.subject.otherDrug delivery devices-
dc.subject.otherCholesterol-
dc.subject.otherDrug prescribing-
dc.subject.otherEconomic analysis-
dc.subject.otherMedical policy-
dc.subject.otherCost effectiveness-
dc.titleTreatment persistence and adherence and their consequences on patient outcomes of generic versus brand-name statins routinely used to treat high cholesterol levels in Spain: a retrospective cost-consequences analysis-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec686011-
dc.date.updated2019-04-03T11:42:45Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid30522491-
Appears in Collections:Articles publicats en revistes (Economia)

Files in This Item:
File Description SizeFormat 
686011.pdf1.32 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons